The Hindu Business Line : Diabetes drug: Dr Reddy’s, Danish co start phase III trials

Hyderabad, Aug 1 Dr Reddy’s Laboratories and the Danish biopharmaceutical company Rheoscience today announced the commencement of the first phase III trial of Balaglitazone (DRF 2593), a potential drug for diabetes.

Balaglitazone, a novel insulin sensitizer, is being developed under a co-development agreement between the two companies. Rheoscience will retain the marketing rights to the EU and China and Dr Reddy’s will have the marketing rights in the territories of the US and rest of the world.

Rheoscience shall obtain all necessary regulatory approvals on behalf of Dr Reddy’s in the US, according to a joint global announcement by the two companies.

With the first patient administered the drug, the study would be the first in a series of planned phase III trials which will investigate the safety and efficacy of Balaglitazone as an oral anti-diabetic drug.

The primary clinical end-point of the study is a glucose lowering effect assessed as a change in haemoglobin A1c (HbA1c) levels — the preferred standard measure of a patient’s blood glucose control over time.

Balaglitazone is a second generation of PPAR (Peroxisome Proliferator-Activated Receptor) gamma agonist with only partial agonistic properties, which in clinical phase II studies have shown to have glucose lowering capabilities and to be body-weight neutral.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Diabetes drug: Dr Reddy’s, Danish co start phase III trials

West Coast Paper plans equities placement to overseas investors

Gujarat NRE Coke back in black

It’s time retail shareholders had their say

Novartis moves HC for new IP Board member

ICICI Venture deal with Ace

Star City plans Australian foray

Binani Cement to invest $100 m in Chinese co

Alok Ind ties up with US co; net rises 104%

Apollo Hospitals plans venture in Mauritius

Toyota Kirloskar Motor yet to decide on small car

GAIL consortium may have hit 2nd dry well in Bengal basin

Earnings of Sensex cos grow 35% in June quarter